Silence Therapeutics PLC Silence Therapeutics Appoints Dr. Marie Wikström (8525D)
02 November 2020 - 6:00PM
UK Regulatory
TIDMSLN
RNS Number : 8525D
Silence Therapeutics PLC
02 November 2020
Silence Therapeutics Appoints Dr. Marie Wikström Lindholm to
its
Executive Leadership Team
- Dr. Lindholm's appointment reflects the Company's commitment to maximise the siRNA opportunity
2 November 2020
LONDON, Silence Therapeutics plc , AIM: SLN and Nasdaq: SLN ("
Silence " or " the Company "), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (siRNA) therapeutics for the treatment of diseases with
significant unmet medical need, today announces that Marie Wikström
Lindholm, PhD, previously VP Head of Technology Innovation, has
been appointed Senior Vice President, Molecular Design and member
of the Silence Executive Leadership Team, effective immediately.
Dr. Lindholm will continue reporting to Silence's Head of R&D
and Chief Medical Officer, Dr. Giles Campion.
Dr. Lindholm joined Silence in December 2017 and has been
responsible for building and leading a skilled team at Silence
focusing on fine-tuning the design of Silence's proprietary
GalNAc-conjugated siRNA technology and exploring siRNA delivery
outside the hepatocyte (liver cell).
Dr. Lindholm has more than 13 years' experience with
oligonucleotide therapeutics, starting with Santaris Pharma A/S,
Denmark, working on locked nucleic acid (LNA) oligonucleotide drug
discovery from molecule design through in vitro screening, in vivo
activity and metabolism studies, and finally a role as lipid
metabolism expert. When Santaris was acquired by Roche in 2014, Dr.
Lindholm was appointed Expert Scientist in Discovery Technology and
Head of Targeted Delivery of oligonucleotide conjugates. She was
also scientific coordinator for the LNA work in two large EU-funded
FP7 programs (AtheroBCell and AtheroFlux).
Before the transition to industry, Dr. Lindholm had an
international academic career in experimental cardiovascular
research starting with a PhD from Uppsala University. She has
authored over 60 patents and peer-reviewed scientific publications,
many in the fields of oligonucleotide drug design, safety, and
function.
Mark Rothera, President and Chief Executive Officer of Silence
Therapeutics, said: "Marie's appointment to Silence's Executive
Leadership Team reflects our commitment to further building our
partnered and internal GalNAc-siRNA pipeline. Marie brings a wealth
of experience working with oligonucleotide therapeutics and she
will also be instrumental in our efforts to expand our siRNA
delivery capabilities outside the liver. We congratulate Marie on
her new role and look forward to her insights and leadership. "
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
U.S. IR Tel: +1 (443) 213-0505
Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
medical need. Silence's proprietary technology can be used to
engineer short interfering ribonucleic acids (siRNAs) that bind
specifically to and silence, through the RNAi pathway, almost any
gene in the human genome to which siRNA can be delivered. Silence's
wholly owned product candidates include SLN360 designed to address
the high and prevalent unmet medical need in reducing
cardiovascular risk in people born with high levels of
Lipoprotein(a) and SLN124 to address beta-thalassemia and
myelodysplastic syndrome. Silence is also developing SLN500, a C3
targeting programme, in partnership with Mallinckrodt
Pharmaceuticals to reduce the expression of the C3 protein for the
treatment of complement pathway-mediated diseases. Silence
maintains ongoing research and collaborations with AstraZeneca,
Mallinckrodt Pharmaceuticals and Takeda. For more information,
please visit: https://www.silence-therapeutics.com/
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements, including with respect to the Company's clinical and
commercial prospects. These forward-looking statements are not
historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements.
These statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties, and other
factors, some of which are beyond the Company's control, are
difficult to predict, and could cause actual results to differ
materially from those expressed or forecasted in the
forward-looking statements. The Company cautions security holders
and prospective security holders not to place undue reliance on
these forward-looking statements, which reflect the view of the
Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAEFFEAXEFAA
(END) Dow Jones Newswires
November 02, 2020 02:00 ET (07:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024